% | $
Quotes you view appear here for quick access.

Incyte Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • sonquiqua sonquiqua Dec 31, 2012 4:47 PM Flag

    110 phase 2 trials

    jacosa, have you seen the phase to in ET for the GERN drug... it seems very promising. They are going after all hematological diseases now, to will go head to head with Jakafi... what's your opinion. Tefferi is conducting a new phase 2 study for GERN

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I'll keep checking on Imetelstat. Looks like a very interesting drug, but midway through exploratory phase 2s a a bit early to make much of a judgement. Tentatively, the mechanism of action is attractive Administration by weekly-to-monthly injection/infusion is highly unattractive. The neutropenia signal is of more concern than with a JAK inhibitor because the 'margination' story doesn't seem on the surface to apply (that is, when JAK inhibitors cause neutropenia, the neutrophils are leaving circulation, but are still available to respond to incipient infection). Frankly, it looks like it is targeted to be a very expensive drug, and that's a problem for ET, which is generally not a severe illness (there are exceptions). In any event, it looks complementary with BAT in all indications rather than being a direct competitor to anything.

88.12-0.60(-0.68%)Jul 28 4:00 PMEDT